Diomed and SonoSite Establish Cooperative Marketing and Education Alliance
February 09 2006 - 8:00AM
Business Wire
Diomed Holdings, Inc. (AMEX: DIO - News), a leading developer and
marketer of minimally invasive medical technologies, including its
patented EndoVenous Laser Treatment (EVLT(R)) for varicose veins,
today announced the formation of a strategic marketing and
educational alliance for the US vein care market with SonoSite,
Inc. (Nasdaq: SONO), the world leader in hand-carried ultrasound.
The agreement is designed to accelerate adoption of both
state-of-the-art, hand-carried ultrasound and laser-based venous
ablation technologies for the diagnosis and treatment of varicose
veins. Under the terms of the three year agreement, the two
companies will offer joint physician training and educational
activities, with particular emphasis on co-sponsored seminars and
workshops, sales force cross-training, lead sharing and other
co-marketing activities in the United States. Ultrasound is a
critical technology used to diagnose venous disease, identify
target areas for vein ablation, and provide image guidance to
position the catheter tip for laser therapy. "We believe Diomed is
an ideal partner for SonoSite in expanding the use of hand-carried
ultrasound in this rapidly growing vein care market," commented
Kevin M. Goodwin, SonoSite President and CEO. "Diomed's leadership
in laser-based venous ablation therapies is a natural complement to
our advanced ultrasound technology." "We are very excited about
joining with SonoSite in this marketing alliance. SonoSite is a
proven innovator in the ultrasound market, and we are confident
that our collaboration will prove beneficial for physicians and
patients alike," stated James A. Wylie, Diomed's President and
Chief Executive Officer. "We believe this agreement provides yet
another example of Diomed's dedication to providing physicians
comprehensive solutions for the treatment of venous disease." About
Diomed Diomed develops and commercializes minimal and
micro-invasive medical procedures that use its proprietary laser
technologies and disposable products. Diomed's EVLT(R) laser vein
ablation procedure is used in varicose vein treatments. Diomed also
provides photodynamic therapy (PDT) for use in cancer treatments,
and dental and general surgical applications. The EVLT(R) procedure
and the Company's related products were cleared by the United
States FDA in January of 2002. Along with lasers and single-use
procedure kits for its EVLT(R) laser vein treatment, the Company
provides its customers with state of the art physician training and
practice development support. Additional information is available
on the Company's website: www.evlt.com. EVLT(R) is a registered
trademark of Diomed Inc., Andover, MA. Safe Harbor Safe Harbor
statements under the Private Securities Litigation Reform Act of
1995: Statements in this news release looking forward in time
involve risks and uncertainties, including the risks associated
with trends in the products markets, reliance on third party
distributors in various countries outside the United States,
reoccurring orders under OEM contracts, market acceptance risks,
technical development risks and other risk factors. These
statements relate to our future plans, objectives, expectations and
intentions. These statements may be identified by the use of words
such as "may," "will," "should," "potential," "expects,"
"anticipates," "intends," "plans," "believes" and similar
expressions. These statements are based on our current beliefs,
expectations and assumptions and are subject to a number of risks
and uncertainties. Our actual results could differ materially from
those discussed in these statements. Our Annual Report on Form SEC
10-KSB (the "Annual Report") contains a discussion of certain of
the risks and uncertainties that affect our business. We refer you
to the "Risk Factors" on pages 22 through 37 of the Annual Report
for a discussion of certain risks, including those relating to our
business as a medical device company without a significant
operating record and with operating losses, our risks relating to
our commercialization of our current and future products and
applications and risks relating to our common stock and its market
value. Diomed disclaims any obligation or duty to update or correct
any of its forward-looking statements. About SonoSite SonoSite,
Inc. (www.sonosite.com) is the innovator and world leader in
hand-carried ultrasound, with an installed base of more than 25,000
systems. The company, headquartered near Seattle, is represented by
eight subsidiaries and a global distribution network in over 75
countries. SonoSite's small, lightweight systems are expanding the
use of ultrasound across the clinical spectrum by cost-effectively
bringing high performance ultrasound to the point of patient care.
The company employs approximately 470 people worldwide.
Sonos (NASDAQ:SONO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sonos (NASDAQ:SONO)
Historical Stock Chart
From Jul 2023 to Jul 2024